Amgen closes epratuzumab trial
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Amgen/Immunomedics terminate a single-agent Phase III study of their humanized antibody epratuzumab (AMG 412) in patients with low grade, follicular, B-cell non-Hodgkin's lymphoma who failed other treatments including rituximab (Genentech/IDEC's Rituxan). The firms attribute the closure to approval of new agents that adequately address medical need since the study's September 2001 opening. Idec's radioimmunotherapy Zevalin (ibritumomab) cleared FDA for NHL Feb. 19, 2002. Epratuzumab development will now focus on use in combination with Rituxan for indolent NHL, and use with Rituxan in a chemotherapy setting for aggressive NH
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.